The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer

Author(s): Steven Tucker

Journal Name: Current Drug Targets

Volume 11 , Issue 1 , 2010

Become EABM
Become Reviewer


Despite improvements in first-line therapy for advanced NSCLC all patients with metastatic disease will progress at some point. Patients with favorable prognostic factors such as good performance status, non-squamous histology, stable weight, and perhaps female gender are more likely to receive second-line chemotherapy. Currently the United States FDA recognizes three single agents (docetaxel, erlotinib, and pemetrexed) as established for providing a benefit in patients who have experienced progression after first-line therapy. This review focuses on the role of PEM in the treatment of advanced NSCLC in patients who have experienced disease progression during or after first-line therapy. The multi-targeted antifolate pemetrexed is equivalent to docetaxel for second-line therapy and with less toxicity.

Keywords: Advanced non-small cell lung cancer, second-line chemotherapy, pemetrexed

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [58 - 60]
Pages: 3
DOI: 10.2174/138945010790031036

Article Metrics

PDF: 11